Recent machine-extracted executive movements from SEC 8-K Item 5.02 filings, source-linked. Every card cites the SEC source.
Showing 7951–8000 of 76387
the Board of Directors (the “Board”) appointed Jonathan Baksht to succeed David V. Barry as Executive Vice President and Chief Financial Officer of the Company effective May 5, 2025.
Mr. Barry will no longer serve as an executive officer of the Company, however, he will continue in his role as President, Security and Connected Products.
On March 31, 2025, the Board of Directors of The Hanover Insurance Group, Inc. (the “Company”) appointed Richard W. Lavey, 58, to serve as Executive Vice President and Chief Operating Officer of the Company, effective on that date.
On April 1, 2025 (the “Effective Date”), Stephanie Pugliese informed American Eagle Outfitters, Inc. (the “Company”) that she was resigning from the Company’s Board of Directors (the “Board”), as of the Effective Date, due to her upcoming appointment as President and Chief Executive Officer of another publicly traded company.
appointed J. Anthony Gallegos, Jr. to the Board to fill the seat vacated by David Bradshaw
On April 1, 2025, Ramsey Alloush, the General Counsel of Journey Medical Corporation (the “ Company ”), was appointed as the Company’s Chief Operating Officer.
Mr. Yumin Liu, Chief Executive Officer (“CEO”), will step down from his role effective April 30, 2025.
The Board of Directors has appointed Ms. Julia Xu, currently an independent director, as Interim CEO, effective May 1, 2025.
On April 2, 2025, Ms. Christine Pambianchi informed Mobileye Global Inc. (the “Company”) of her resignation from the board of directors (the “Board”), effective April 25, 2025 in connection with her resignation as executive vice president and chief people officer of Intel Corporation, the Company’s controlling shareholder.
Mr. Carrel-Billiard currently serves as the Seller’s Head of Real and Alternative Assets and has been appointed as a Class III director.
Ms. Boyer-Chammard currently serves as the Seller’s Head of Sustainable Transformation and Organization and has been appointed as a Class II director.
The Company announced that Bob Hurst, one of Crestview Partners’ nominees on the Company’s board of directors (the “Board”), retired from the Board effective as of April 1, 2025
On April 3, 2025, the Board of Directors (the “Board”) of Ingersoll Rand Inc. (the “Company”), upon the recommendation of its Nominating and Corporate Governance Committee, appointed Michelle Swanenburg as a director of the Board, effective April 3, 2025
each of the directors of Nevro (D. Keith Grossman, Michael DeMane, Kirt Karros, Sri Kosaraju, Shawn T. McCormick, Kevin O’Boyle, Karen N. Prange, Susan Siegel, Kevin Thornal and Elizabeth Weatherman) resigned from the Board.
each of the directors of Nevro (D. Keith Grossman, Michael DeMane, Kirt Karros, Sri Kosaraju, Shawn T. McCormick, Kevin O’Boyle, Karen N. Prange, Susan Siegel, Kevin Thornal and Elizabeth Weatherman) resigned from the Board.
each of the directors of Nevro (D. Keith Grossman, Michael DeMane, Kirt Karros, Sri Kosaraju, Shawn T. McCormick, Kevin O’Boyle, Karen N. Prange, Susan Siegel, Kevin Thornal and Elizabeth Weatherman) resigned from the Board.
each of the directors of Nevro (D. Keith Grossman, Michael DeMane, Kirt Karros, Sri Kosaraju, Shawn T. McCormick, Kevin O’Boyle, Karen N. Prange, Susan Siegel, Kevin Thornal and Elizabeth Weatherman) resigned from the Board.
each of the directors of Nevro (D. Keith Grossman, Michael DeMane, Kirt Karros, Sri Kosaraju, Shawn T. McCormick, Kevin O’Boyle, Karen N. Prange, Susan Siegel, Kevin Thornal and Elizabeth Weatherman) resigned from the Board.
each of the directors of Nevro (D. Keith Grossman, Michael DeMane, Kirt Karros, Sri Kosaraju, Shawn T. McCormick, Kevin O’Boyle, Karen N. Prange, Susan Siegel, Kevin Thornal and Elizabeth Weatherman) resigned from the Board.
each of the directors of Nevro (D. Keith Grossman, Michael DeMane, Kirt Karros, Sri Kosaraju, Shawn T. McCormick, Kevin O’Boyle, Karen N. Prange, Susan Siegel, Kevin Thornal and Elizabeth Weatherman) resigned from the Board.
each of the directors of Nevro (D. Keith Grossman, Michael DeMane, Kirt Karros, Sri Kosaraju, Shawn T. McCormick, Kevin O’Boyle, Karen N. Prange, Susan Siegel, Kevin Thornal and Elizabeth Weatherman) resigned from the Board.
each of the directors of Nevro (D. Keith Grossman, Michael DeMane, Kirt Karros, Sri Kosaraju, Shawn T. McCormick, Kevin O’Boyle, Karen N. Prange, Susan Siegel, Kevin Thornal and Elizabeth Weatherman) resigned from the Board.
each of the directors of Nevro (D. Keith Grossman, Michael DeMane, Kirt Karros, Sri Kosaraju, Shawn T. McCormick, Kevin O’Boyle, Karen N. Prange, Susan Siegel, Kevin Thornal and Elizabeth Weatherman) resigned from the Board.
each of Daniel Scavilla and Keith Pfeil, the directors of Merger Sub immediately prior to the Effective Time, became the directors of Nevro.
each of Daniel Scavilla and Keith Pfeil, the directors of Merger Sub immediately prior to the Effective Time, became the directors of Nevro.
On March 31, 2025, Eyal C. Attar, M.D., notified Vor Biopharma Inc. (the “Company”) of his decision to resign as Chief Medical Officer of the Company, effective as of April 18, 2025, in order to pursue a new opportunity.
On April 3, 2025, the Board of Directors of the Company appointed Rob Dolski, the Company’s current Chief Financial Officer, to serve as the principal accounting officer of the Company in addition to his current role as principal financial officer, effective immediately.
On February 24, 2025, Andrew Mercieca notified Autolus Therapeutics plc (the “Company”) of his intention to resign from his role as the Company’s Vice President of Finance and principal accounting officer, to pursue another opportunity.
pursuant to which Mr. Abuaita will transition from his current role to a new position as a Senior Advisor to the Company effective May 1, 2025
On March 31, 2025, Donna L. DeCarolis, President of National Fuel Gas Distribution Corporation, provided notice to National Fuel Gas Company of her intention to retire, effective July 1, 2025.
On March 31, 2025, the Board appointed Charles (“Chip”) Victor Bergh to the Board as a Class III director, effective as of April 1, 2025, with an initial term expiring at the Company’s 2025 annual meeting of stockholders.
On March 31, 2025, Beth Pritchard notified e.l.f. Beauty, Inc. (the “ Company ”) of her decision to resign from the Company’s Board of Directors (the “ Board ”) and all committees thereof, effective March 31, 2025.
Sumita Pandit, currently serving as Senior Executive Vice President, Chief Financial Officer of the Company, will become President and Chief Financial Officer of the Company upon Mr. Brummer’s retirement from his current role
On March 28, 2025, the Company and Mr. Brummer agreed to accelerate the date of Mr. Brummer’s retirement from his current role to April 21, 2025.
Robert E. Grove has agreed to resign and has submitted his resignation to the Company’s Board and all committees thereof, effective as of April 2, 2025.
On March 31, 2025, the Board, on the recommendation of the Corporate Governance and Nominating Committee, appointed John A. Fichthorn as a director, effective April 3, 2025
On April 3, 2025, the Board of Directors (the “Board”) of Quantum Corporation (the “Company”) appointed Lewis W. Moorehead, the Company’s Vice President of Finance and Treasurer, to serve as the Company’s Chief Financial Officer and Principal Financial Officer, effective as of April 4, 2025.
Mr. Moorehead succeeds Kenneth P. Gianella, who will be transitioning out of his current role as Chief Operating Officer, Chief Financial Officer and Principal Financial Officer, effective April 3, 2025
Effective April 2, 2025, Todd W. Arden, a member of the Board, informed the Company of his decision to resign from the Board.
On April 2, 2025, the Company appointed Karina Fedasz, 52, the Company’s Interim Chief Financial Officer, as Interim Chief Executive Officer of the Company, effective immediately.
Effective as of March 28, 2025, James Sapirstein resigned as Executive Chairman and a member of the Board of Directors (the “Board”) of Onconetix, Inc. (the “Company”).
Effective as of March 31, 2025, the Board of Directors (the “Board”) of the Company appointed Uri Levine, as a member and Chairman of the Board
On April 1, 2025, in connection with the IPO, Neil Leibman, Warren Thompson, and David Perlin (collectively with Steve Salis and Jamie Karson, the “Directors”) were appointed to the board of directors of the Company (the “Board”).
On April 1, 2025, in connection with the IPO, Neil Leibman, Warren Thompson, and David Perlin (collectively with Steve Salis and Jamie Karson, the “Directors”) were appointed to the board of directors of the Company (the “Board”).
On April 1, 2025, in connection with the IPO, Neil Leibman, Warren Thompson, and David Perlin (collectively with Steve Salis and Jamie Karson, the “Directors”) were appointed to the board of directors of the Company (the “Board”).
On March 29, 2025, Chetan Gulati, Leo Gontmakher, and Roman Tkachenko resigned from the Board of Directors of 4Front Ventures Corp.
On March 29, 2025, Chetan Gulati, Leo Gontmakher, and Roman Tkachenko resigned from the Board of Directors of 4Front Ventures Corp.
On March 29, 2025, Chetan Gulati, Leo Gontmakher, and Roman Tkachenko resigned from the Board of Directors of 4Front Ventures Corp.
Effective April 3, 2025, the Board of Directors (the “Board”) of FutureFuel Corp. (the “Company”) increased the size of the Board to nine members and the Company appointed Pamela R. Butcher as a Class C member of the Board until her successor is duly elected and qualified or until her earlier death, resignation or removal.
Matthew Edelman was appointed as Chief Executive Officer (“ CEO ”) of the Company, effective April 1, 2025
Recent executive movements from 8-K Item 5.02 filings, source-linked. Cards are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.